Gala Presents Positive Results from First-In-Human Clinical Trial of RheOx(TM) in Chronic Bronchitis at the European Respiratory Society

Favorable safety profile RheOx treatment resulted in clinical improvement as measured by Quality of Life scores, with treatment effect maintained at 12-month follow-up Improvement in airway biopsies and imaging MENLO PARK, Calif., Sept. 17, 2018 -... Biopharmaceuticals Gala Therapeutics, RheOx, chronic bronchitis, Bronchial Rheoplasty
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news